Drug Profile
Interferon-beta-1b - Toray/Daiichi Sankyo
Alternative Names: DL-8234; Feron; Interferon-beta-1bLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Toray
- Developer Daiichi Sankyo Company; Toray
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Immunomodulators; Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Brain cancer; Glioblastoma; Hepatitis B; Hepatitis C; Malignant melanoma
- Registered Liver cirrhosis
- Discontinued Age-related macular degeneration; Liver cancer
Most Recent Events
- 24 Mar 2015 The product is approved for Cirrhosis in Japan
- 16 Oct 2009 Registered for Hepatitis C in combination with ribavirin in Japan (IV)
- 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc